BCPT

Breast Cancer Prevention Trial. A study of 13388 women at increased risk of breast cancer (BC): in women age 60+, < age 60 but at increased risk of BC, or with history of lobular carcinoma in situ, and randomised to receive tamoxifen or placebo.

Results
Tamoxifen reduces the risk of invasive BC by 49%; despite its side effects—e.g., increased risk of endometrial cancer, RR 2.53, stroke, pulmonary embolism and deep vein thrombosis—its use as a prophylaxis is appropriate in high-risk women.

All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.